Prof. Richard Finn on Finding a Biomarker for Patients with HCC −

Biomarker selection for systemic treatments has become a challenge in this particular field, Prof. Finn says. Factors that are currently considered are performance status, underlying liver function, and tolerability of systemic treatment. Researchers still have not determined a biomarker for patients to receive either sorafenib (Nexavar) or regorafenib (Stivarga).

Read more